澳华内镜(688212) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 169,298,973.87, representing a year-on-year increase of 34.91%[5]. - Total operating revenue for Q1 2024 reached ¥169.30 million, a 35% increase from ¥125.49 million in Q1 2023[18]. - The net profit for Q1 2024 was CNY 9,321,245.81, down 34.5% from CNY 14,239,211.16 in Q1 2023[26]. - Net profit for Q1 2024 was ¥2.55 million, down 84% from ¥16.47 million in Q1 2023[19]. - The total comprehensive income for Q1 2024 was ¥1.25 million, a decrease of 93% from ¥16.97 million in Q1 2023[19]. Expenses and Costs - Research and development expenses totaled CNY 44,482,962.56, which is an increase of 39.70% compared to the previous year, accounting for 26.27% of operating revenue[5][8]. - Total operating costs increased to ¥176.93 million in Q1 2024, up from ¥121.18 million in Q1 2023, representing a 46% rise[18]. - The company experienced a significant increase in sales expenses, which rose to ¥63.58 million from ¥41.52 million, a 53% increase year-over-year[18]. - The company reported a decrease in sales expenses to CNY 60,587,639.73 in Q1 2024 from CNY 39,365,684.58 in Q1 2023[25]. Cash Flow - The net cash flow from operating activities was negative at CNY -104,090,525.46, attributed to increased personnel expenses and reduced sales collections[7]. - The company reported a net cash outflow from operating activities of ¥104.09 million in Q1 2024, compared to an outflow of ¥30.80 million in Q1 2023[21]. - Cash flow from operating activities was CNY 115,682,097.71 in Q1 2024, down from CNY 130,760,766.39 in Q1 2023[27]. - The company reported a total cash outflow of $109.25 million for the quarter, compared to $59.70 million in Q1 2023[28]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,596,435,026.38, a slight increase of 0.09% from the end of the previous year[5]. - The company's current assets decreased to RMB 977,540,677.12 from RMB 1,008,181,335.04, representing a decline of approximately 3.5%[14]. - The total liabilities decreased to RMB 176,329,643.17 from RMB 199,884,992.04, a reduction of about 11.8%[16]. - The company's total liabilities decreased to CNY 153,128,485.90 in Q1 2024 from CNY 168,015,854.10 in Q4 2023[24]. Shareholder and Equity Information - The net profit attributable to shareholders decreased by 83.32% to CNY 2,759,505.20, primarily due to increased personnel costs related to the restricted stock incentive plan[5][7]. - The basic and diluted earnings per share both decreased by 83.33% to CNY 0.02[5]. - The owner's equity increased to RMB 1,420,105,383.21 from RMB 1,395,158,777.46, marking a growth of approximately 1.8%[16]. - The total equity increased to CNY 1,382,354,515.81 in Q1 2024, compared to CNY 1,348,891,384.29 in Q4 2023[25]. Strategic Initiatives - The company launched a new round of equity incentive plans in October 2023, which significantly impacted the net profit for the reporting period[7]. - The increase in operating revenue was driven by the strong performance of the AQ300 product line[7]. - The company has ongoing investments in new technologies and product development, although specific figures are not detailed in the provided content[17]. Cash and Cash Equivalents - The company's cash and cash equivalents were reported at RMB 108,263,015.62, down from RMB 244,547,569.15, a significant decrease of about 55.8%[14]. - Cash and cash equivalents at the end of Q1 2024 were ¥108.26 million, down from ¥188.69 million at the end of Q1 2023[22]. - The company's cash and cash equivalents decreased to CNY 87,078,987.30 as of March 31, 2024, from CNY 196,326,434.61 at the end of 2023[23].